Asset Details
Do you wish to reserve the book?
Tirzepatide Once Weekly for the Treatment of Obesity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tirzepatide Once Weekly for the Treatment of Obesity
Do you wish to request the book?
Tirzepatide Once Weekly for the Treatment of Obesity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tirzepatide Once Weekly for the Treatment of Obesity
2022
Overview
In this randomized trial, adults with obesity treated with weekly tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, had major weight loss over 72 weeks.
Publisher
Massachusetts Medical Society
Subject
/ Anti-Obesity Agents - administration & dosage
/ Anti-Obesity Agents - pharmacology
/ Anti-Obesity Agents - therapeutic use
/ Diabetes
/ Diet
/ Dose-Response Relationship, Drug
/ Gastric Inhibitory Polypeptide - administration & dosage
/ Gastric Inhibitory Polypeptide - therapeutic use
/ Glucagon
/ Glucagon-Like Peptides - administration & dosage
/ Glucagon-Like Peptides - agonists
/ Glucagon-Like Peptides - therapeutic use
/ Humans
/ Obesity
/ Peptides
/ Placebos
